Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510816 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
A Phase 3 study of Geographic Atrophy, sponsored by Annexon.
- Active
- Registry status
- Phase 3
- Development phase
- 659
- Enrollment target
- 20
- Study locations
NCT06510816: Active Phase 3 study of Geographic Atrophy, sponsored by Annexon.
NCT06510816 is a Phase 3 study of Geographic Atrophy that is active but no longer recruiting, run by Annexon. The registered enrollment target is 659 participants, above the 198-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (233% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06510816, a Phase 3 study of Geographic Atrophy, is active but no longer recruiting, sponsored by Annexon.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 659 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Conditions Studied
Interventions
- OTHER Sham Administration
- DRUG Vonaprument
Study Locations (20)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- RCOC Clinical Research Institute Inc - Fullerton
- Global Research Management - Glendale
- Retina Consultants Medical Group - Modesto
- Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
- Retinal Consultants Medical Group - Sacramento
- Macula Retina Vitreous Research Institute - Torrance
- Bay Area Retina Associates - Walnut Creek
Florida
- Rand Eye Institute - Deerfield Beach
- National Ophthalmic Research Institute - Fort Myers
- Florida Retina Institute - Orlando
- Fort Lauderdale Eye Institute - Plantation
- Retina Group of Florida - Sarasota
- Retina Vitreous Associates of Florida - St. Petersburg
- East Florida Eye Institute - Stuart
Colorado
- Retina Consultants of Southern Colorado PC - Colorado Springs
- RSC Research, LLC - Denver
Arizona
- Retina Macula Institute of Arizona - Scottsdale
Georgia
- Georgia Retina PC - Marietta
Hawaii
- Retina Consultants of Hawaii - ‘Aiea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2024-07-30 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
What the registry record for NCT06510816 still lists
NCT06510816 is an interventional study that assigns participants to a tested intervention. The registered 659 participants enrollment target is mid-sized for trials with a published cap, above the 198-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (233% higher).
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Sham Administration is the first listed.
NCT06510816 names 20 study sites across 6 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT06510816 about?
NCT06510816 is a clinical study titled "A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)". The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT06510816?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 659 participants. The study started on 2024-07-30. Estimated completion is 2027-10-31.
What conditions does trial NCT06510816 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT06510816?
The interventions under investigation include: Sham Administration (OTHER), Vonaprument (DRUG).
Who is sponsoring clinical trial NCT06510816?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510816 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06510816's enrollment target sits among peer trials
659 2nd of 27 the highest of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
COMPLETED · Phase 3
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
High Resolution Retinal Imaging
RECRUITING
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI